<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9815">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689632</url>
  </required_header>
  <id_info>
    <org_study_id>CVH-D3K2</org_study_id>
    <nct_id>NCT05689632</nct_id>
  </id_info>
  <brief_title>Vitamins D and K Effects on Vascular Function in Obese Adults.</brief_title>
  <official_title>Effects of Vitamin D3 and Vitamin K2MK7 Supplementation on Vascular Function in Overweight or Obese Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Pedro Ernesto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Pedro Ernesto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, placebo-controlled, double-blind study that aims to evaluate the&#xD;
      effects of combined vitamin D3 and K2-MK7 supplementation on vascular function, sympathetic&#xD;
      tone, metabolic biomarkers and inflammatory factors in a population of overweight or obese&#xD;
      adults and deficient or insufficient serum levels of vitamin D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overweight and obesity are public health issues of epidemic proportions nowadays. They&#xD;
      constitute risk factors for several chronic diseases with vascular, metabolic, and&#xD;
      inflammatory changes. Adequate serum levels of vitamin D are correlated with good&#xD;
      cardiovascular and metabolic health, since its deficiency and insufficiency (highly prevalent&#xD;
      in obesity) have an inverse correlation. Likewise, vitamin K, especially K2, is related to&#xD;
      the reduction of arterial stiffness, suppression of the inflammation in the vascular wall,&#xD;
      favorable action on the lipid profile, whereas insufficiency is related to increased&#xD;
      cardiovascular risk. The combined use of vitamin D and K aiming to reduce cardiovascular risk&#xD;
      has been studied, however, the results of randomized clinical trials are still controversial.&#xD;
      This prospective, randomized, placebo-controlled, double-blind trial aims to evaluate the&#xD;
      effect of supplementation of vitamins D3 and K2-MK7 on vascular function, sympathetic tone,&#xD;
      metabolic biomarkers and inflammatory factors in a population of overweight or obese adults&#xD;
      and serum levels of deficient or insufficient vitamin D. Individuals of both sexes, aged&#xD;
      between 40 and 70 years, body mass index (BMI) ≥ 25 and &lt; 40 kg/m² and vitamin 25OHD3 &lt;30&#xD;
      ng/ml will be randomized into 3 groups (A/B/C) to receive supplementation (Placebo/VitD3 7000&#xD;
      IU/VitD3 7000IU+K2-MK7-180mcg) daily for 16 weeks. Individuals will be rated at 4 visits&#xD;
      namely:&#xD;
&#xD;
        -  V0 screening according to inclusion and exclusion criteria; clinical, anthropometry and&#xD;
           electrical bioimpedance, laboratory and vascular evaluation before supplementation;&#xD;
&#xD;
        -  V1 supplementation begins;&#xD;
&#xD;
        -  V2 after 8 weeks;&#xD;
&#xD;
        -  V3 at the end of the intervention. The laboratory evaluation consists of blood count,&#xD;
           biochemistry, electrolytes, glucose, lipid, liver and thyroid profiles, vitamin D3 and&#xD;
           parathyroid hormone, in addition to the urinary excretion of calcium and creatinine.&#xD;
           Sympathetic tone is assessed by a frequency meter (Polar® Verity Sense), arterial&#xD;
           stiffness by measuring the pulse wave velocity by oscillometry (Mobil-O-Graph®) and&#xD;
           endothelium function by measuring post-occlusion microvascular reactivity using laser&#xD;
           speckle contrast image-LSCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2022</start_date>
  <completion_date type="Anticipated">November 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, placebo-controlled, double-blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The participants and the investigator do not know which supplements are taken.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular reactivity</measure>
    <time_frame>150 minutes</time_frame>
    <description>A laser speckle contrast imaging system with a laser wavelength of 785 nm system will measure non-invasively real time cutaneous microvascular flow changes in the forearm. For the post occlusive reactive hyperemia test, arterial occlusion will be performed with suprasystolic pressure (50 mmHg above the systolic arterial pressure) using a sphygmomanometer applied to the arm of the subject over three minutes. Peak skin flow will be measured after pressure release.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central blood pressure</measure>
    <time_frame>150 minutes</time_frame>
    <description>Central systolic blood pressure, diastolic blood pressure, mean arterial pressure and pulse pressure before and after intervention and their potential effects on changes in subendocardial viability ratio and ejection duration after intervention with beetroot juice and water.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <condition>Vitamin D3 Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - Medium-chain triglyceride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 - 7000 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 + K2-MK7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 - 7000 IU + Vitamin K2-MK7 180mcg combined, daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 + K2-MK7</intervention_name>
    <description>Combined supplementation</description>
    <arm_group_label>Vitamin D3 + K2-MK7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>MCT</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 - 7000 IU</description>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Vitamin D deficiency;&#xD;
&#xD;
          -  Vitamin D insufficiency;&#xD;
&#xD;
          -  Obesity;&#xD;
&#xD;
          -  Overweight;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus;&#xD;
&#xD;
          -  Arterial coronary disease;&#xD;
&#xD;
          -  Beta blocker use;&#xD;
&#xD;
          -  cancer;&#xD;
&#xD;
          -  ESRD;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana C Faria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario F Neves, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>State University of Rio de Janeiro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adriana C Faria, MD</last_name>
    <phone>5521999834054</phone>
    <email>afmenie@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario F Neves, MD, PhD</last_name>
    <email>mariofneves@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rio de Janeiro State University</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana C Faria, MD</last_name>
      <phone>5521999834054</phone>
      <email>afmenie@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 10, 2023</last_update_submitted>
  <last_update_submitted_qc>January 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Pedro Ernesto</investigator_affiliation>
    <investigator_full_name>Mario Fritsch Neves</investigator_full_name>
    <investigator_title>FULL PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Vitamin D3 Deficiency</keyword>
  <keyword>Vitamin K</keyword>
  <keyword>Sympathetic tonus</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Arterial stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share IPD with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

